# Tandem Diabetes Care (TNDM) — Earnings

TNDM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tndm/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.31 |
| EPS estimate | −$0.32 |
| EPS surprise | +4.37% |
| Revenue surprise | −0.17% |
| Revenue | $254.6M |
| Revenue estimate | $255.0M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1438133/000143813326000125/tndm-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/a2911c4e-bc51-40aa-8326-c731b9080806.html) |

Tandem Diabetes Care reported Q2 2026 results on August 6, 2026. The company posted a loss of $0.31 per share, slightly narrower than the $0.32 loss expected, a 4.37% beat. Revenue was $254.6 million, just under the $255.0 million consensus. Compared with Q2 2025, the loss narrowed from $0.48 per share and revenue rose about 6% from $240.7 million.

Tandem lost money in 17 of the last 20 quarters; the profitable ones were Q3 2021, Q4 2021 and Q4 2024. Annual losses were $1.48 per share in 2022, $3.44 in 2023, $1.46 in 2024 and $1.47 in 2025. Revenue has grown, from $762.3 million in 2023 to $1.01 billion in 2025, and the fourth quarter has been the strongest of each recent year, with Q4 2025 setting the high here at $290.4 million. The first-half 2026 loss of $0.61 per share compares with $1.15 a year earlier. Tandem beat the EPS estimate in 9 of the last 20 quarters, including 6 of the last eight.

Third-quarter results have come out between November 1 and November 6 in each of the past five years. That points to early November 2026 for the Q3 2026 report.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.32 | −$0.31 | 4.37% | $255.0M | $254.6M |
| Q1 2026 | May 7, 2026 | −$0.44 | −$0.30 | 32.79% | $240.4M | $247.2M |
| Q4 2025 | Feb 19, 2026 | −$0.09 | −$0.01 | 90.42% | $277.0M | $290.4M |
| Q3 2025 | Nov 6, 2025 | −$0.33 | −$0.31 | 4.98% | $235.8M | $249.3M |
| Q2 2025 | Aug 6, 2025 | −$0.40 | −$0.48 | -20.93% | $238.6M | $240.7M |
| Q1 2025 | Apr 30, 2025 | −$0.60 | −$0.67 | -10.61% | $220.3M | $234.4M |
| Q4 2024 | Feb 26, 2025 | −$0.20 | $0.01 | 104.90% | $250.6M | $252.4M |
| Q3 2024 | Nov 6, 2024 | −$0.40 | −$0.35 | 13.17% | $224.1M | $242.9M |
| Q2 2024 | Aug 1, 2024 | −$0.54 | −$0.47 | 12.18% | $205.6M | $221.8M |
| Q1 2024 | May 2, 2024 | −$0.76 | −$0.65 | 14.19% | $174.5M | $192.8M |
| Q4 2023 | Feb 21, 2024 | −$0.26 | −$0.46 | -74.31% | $203.5M | $209.4M |
| Q3 2023 | Nov 1, 2023 | −$0.48 | −$0.51 | -6.10% | $192.8M | $185.6M |
| Q2 2023 | Aug 3, 2023 | −$0.50 | −$0.55 | -9.17% | $197.6M | $195.9M |
| Q1 2023 | May 3, 2023 | −$0.54 | −$1.92 | -256.55% | $170.3M | $171.4M |
| Q4 2022 | Feb 22, 2023 | −$0.08 | −$0.25 | -207.88% | $221.0M | $220.5M |
| Q3 2022 | Nov 2, 2022 | −$0.07 | −$0.76 | -1053.26% | $207.6M | $205.1M |
| Q2 2022 | Aug 3, 2022 | $0.02 | −$0.24 | -1463.64% | $205.2M | $200.3M |
| Q1 2022 | May 4, 2022 | −$0.07 | −$0.23 | -226.70% | $168.2M | $175.9M |
| Q4 2021 | Feb 22, 2022 | $0.21 | $0.16 | -23.66% | $199.0M | $210.0M |
| Q3 2021 | Nov 3, 2021 | $0.06 | $0.09 | 57.62% | $171.4M | $179.6M |

## Frequently Asked Questions

### When did Tandem Diabetes Care (TNDM) last report earnings?

Tandem Diabetes Care last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did TNDM beat earnings estimates?

Yes. Tandem Diabetes Care reported EPS of −$0.31 for Q2 2026 against a −$0.32 estimate — a 4.37% beat.

### How much revenue did TNDM report last quarter?

Tandem Diabetes Care reported $254.6M in revenue for Q2 2026, against a consensus estimate of $255.0M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).